Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374998 | 0.89 | HRH4 (0.38) | HPGDKDM4ETSHRHSP90AA1ALDH1A1 | |
| SCHEMBL6368753 | 0.79 | HPGD (0.57) | HPGDSMN1; SMN2KDM4ETSHRRECQL | |
| SCHEMBL6368587 | 0.78 | HPGD (0.55) | HPGDSMN1; SMN2KDM4ETSHRRECQL | |
| SCHEMBL6777423 | 0.77 | KDM4E (0.43) | HPGDSMN1; SMN2KDM4ETSHRALDH1A1 | |
| SCHEMBL6374548 | 0.72 | DHFR (0.31) | — | |
| SCHEMBL6369872 | 0.70 | HPGD (0.46) | HPGDSMN1; SMN2KDM4ETSHRHSP90AA1 | |
| SCHEMBL22225997 | 0.69 | HPGD (0.64) | HPGDSMN1; SMN2TSHRRECQLALDH1A1 | |
| SCHEMBL6368985 | 0.68 | HPGD (0.46) | HPGDSMN1; SMN2KDM4ETSHRHSP90AA1 | |
| SCHEMBL22226359 | 0.68 | HPGD (0.42) | HPGDSMN1; SMN2KDM4ETSHRRECQL | |
| SCHEMBL6369845 | 0.68 | HPGD (0.44) | HPGDSMN1; SMN2KDM4ETSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | GAMMILL RONALD B (US) | 2005-01-27 | — | — | US | claimed |
| US-20030199553-A1 | Antidiabetic agents | GAMMILL RONALD B (US) | 2003-10-23 | — | — | US | claimed |
| WO-2003072570-A1 | ANTIDIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-1340500-A1 | Antidiabetic agents | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | claimed |
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | GAMMILL RONALD B (US) | 2005-01-27 | — | — | US | disclosed |
| US-6821977-B2 | SUBSTITUTED 1H-(INDOLE-2- CARBOXAMIDES AND 6H-THIENO(2,3-B)PYRROLE-5-CARBOXAMIDES USEFUL FOR INHIBITING GLYCOGEN PHOSPHORYLASE IN A MAMMAL | PFIZER, INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030199553-A1 | Antidiabetic agents | GAMMILL RONALD B (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003072570-A1 | ANTIDIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1340500-A1 | Antidiabetic agents | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199553-A1 | Antidiabetic agents | GPR119, IRS1, INSR | HPGD 1956/4885SMN1; SMN2 2393/4885KDM4E 4333/4885 |
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | PYGM, PYGL, IRS1 | HPGD 2567/4885SMN1; SMN2 3622/4885KDM4E 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.